Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04666441 · ClinicalTrials.gov registry record · Phase 2
COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection
A Phase 2 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,149
- Enrollment target
NCT04666441: Completed Phase 2 study, sponsored by Regeneron Pharmaceuticals.
NCT04666441 is a Phase 2 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 1,149 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (764% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04666441, a Phase 2 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,149 participants
- Enrollment target
Study Summary
The primary objective of the study is to assess the virologic efficacy of REGN10933+REGN10987 across different intravenous and subcutaneous doses compared to placebo. The secondary objectives of the study are: * To evaluate additional indicators of virologic efficacy of REGN10933+REGN10987 compared to placebo * To evaluate the safety and tolerability of REGN10933+REGN10987 compared to placebo * To assess the concentrations of REGN10933 and REGN10987 in serum over time * To assess the immunogenicity of REGN10933 and REGN10987
Primary Outcome
Time-weighted average daily change from Day 1 in viral load (log10 copies/mL), as measured by reverse transcription quantitative polymerase chain reaction (RT-qPCR) in nasopharyngeal (NP) swab samples.
Interventions
- DRUG Placebo
- DRUG REGN10933+REGN10987 combination therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,149 participants |
| Start Date | 2020-12-15 |
| Est. Completion | 2021-09-21 |
| Phase | Phase 2 |
What the finished NCT04666441 record still lists
NCT04666441 is an interventional study that assigns participants to a tested intervention. Its 1,149 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (764% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04666441 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04666441 about?
NCT04666441 is a clinical study titled "COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection". The primary objective of the study is to assess the virologic efficacy of REGN10933+REGN10987 across different intravenous and subcutaneous doses compared to placebo. The secondary objectives of the study are: * To evaluate additional indicators of virologic efficacy of REGN10933+REGN10987 compare...
What is the current status of trial NCT04666441?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,149 participants. The study started on 2020-12-15. Estimated completion is 2021-09-21.
What interventions are being tested in trial NCT04666441?
The interventions under investigation include: Placebo (DRUG), REGN10933+REGN10987 combination therapy (DRUG).
Who is sponsoring clinical trial NCT04666441?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04666441's enrollment target sits among peer trials
1,149 19th of 2000 higher than 1,982 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06408181 · 1,150 participants · Phase 3
APPLE: Aspirin to Prevent Pregnancy Loss and Preeclampsia
- NCT06528314 · 1,150 participants · Phase 3
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- NCT07293559 · 1,150 participants
Understanding Practices of Lactation and Infant Feeding Together With Women With HIV in the United States
- NCT07339423 · 1,150 participants · Phase 3
AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI